Citigroup’s SAGENT PHARMACEUTICALS INC COM STK (DE) SGNT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q3 | – | Sell |
-15,314
| Closed | -$229K | – | 7363 |
|
|
2016
Q2 | $229K | Sell |
15,314
-4,413
| -22% | -$56.7K | ﹤0.01% | 4366 |
|
|
2016
Q1 | $239K | Buy |
19,727
+12,193
| +162% | +$171K | ﹤0.01% | 4913 |
|
|
2015
Q4 | $119K | Sell |
7,534
-2,827
| -27% | -$44.5K | ﹤0.01% | 5237 |
|
|
2015
Q3 | $159K | Sell |
10,361
-733
| -7% | -$15.8K | ﹤0.01% | 4677 |
|
|
2015
Q2 | $271K | Buy |
11,094
+1,823
| +20% | +$43.7K | ﹤0.01% | 4205 |
|
|
2015
Q1 | $216K | Sell |
9,271
-2,385
| -20% | -$63.1K | ﹤0.01% | 4465 |
|
|
2014
Q4 | $292K | Buy |
11,656
+352
| +3% | +$10.3K | ﹤0.01% | 4382 |
|
|
2014
Q3 | $352K | Buy |
11,304
+34
| +0.3% | +$921 | ﹤0.01% | 3806 |
|
|
2014
Q2 | $292K | Sell |
11,270
-5,411
| -32% | -$120K | ﹤0.01% | 3825 |
|
|
2014
Q1 | $389K | Sell |
16,681
-54
| -0.3% | -$1.18K | ﹤0.01% | 3715 |
|
|
2013
Q4 | $424K | Buy |
16,735
+15,344
| +1,103% | +$346K | ﹤0.01% | 3960 |
|
|
2013
Q3 | $28K | Buy |
1,391
+99
| +8% | +$2.2K | ﹤0.01% | 5714 |
|
|
2013
Q2 | $27K | Buy |
+1,292
| New | +$23.1K | ﹤0.01% | 5696 |
|
Citigroup's SGNT Position: Q3 2016 in Review
Citigroup sold out of SAGENT PHARMACEUTICALS INC COM STK (DE) (SGNT) in Q3 2016, closing a stake of 15,314 shares — an estimated $229K sold.
Citigroup first reported a position in SGNT in Q2 2013 and held it in 13 quarters. The position peaked at $424K in Q4 2013. 0 funds tracked by Wall St. Rank hold SGNT as of Q3 2016.
- Citigroup reported no remaining SAGENT PHARMACEUTICALS INC COM STK (DE) position as of Q3 2016 after selling out during the quarter.
- Citigroup sold 15,314 SAGENT PHARMACEUTICALS INC COM STK (DE) shares in Q3 2016, an estimated $229K.
- Citigroup first reported a position in SAGENT PHARMACEUTICALS INC COM STK (DE) in Q2 2013 and held it in 13 quarters.
- Citigroup's SAGENT PHARMACEUTICALS INC COM STK (DE) position peaked at $424K in Q4 2013.
- 0 funds tracked by Wall St. Rank held SAGENT PHARMACEUTICALS INC COM STK (DE) as of Q3 2016.
Based on Citigroup's 13F filing for Q3 2016, filed 10 Nov 2016.